Our investment strategy is rooted in identifying and scaling high-potential companies across key life sciences sub-sectors, focusing on cutting-edge technologies with the power to transform patient outcomes and reshape markets.
Our team sets us apart: a group of seasoned entrepreneurs, operators, and investors who bring deep industry expertise and a hands-on approach. From initial investment through exit, we partner closely with founders to accelerate growth, unlock value, and build lasting businesses that make a difference.
The Kineticos Capital Partners fund series targets lower mid-market pharma services companies. With a focus on driving organic growth, expanding offerings, executing strategic acquisitions, and pursuing international opportunities, our fund partners with management teams to scale platforms into market leaders.
Learn More
The AMR Accelerator Fund is dedicated to combating antimicrobial resistance by investing in early-stage innovators. We back visionary teams focused on solving one of healthcare’s most pressing global challenges through breakthrough technologies.
Learn More
The Kineticos Disruptor Fund series invests in early-stage life science companies advancing groundbreaking technologies to treat cancer, neurodegenerative, and rare diseases. We support leading-edge founders pushing the boundaries of science to create the next wave of patient-focused innovation.
Learn More){kind=logo}
Phase 1b/2a study in cystic fibrosis remains on track for full enrollment by end of 2025 following positive interim analysis…
){kind=logo}
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by…
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…